JYNT:NASDAQThe Joint Corp. Analysis
Data as of 2026-05-19 - not real-time
$8.73
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
The Joint Corp. (JYNT) is trading at $8.73, just above its 20‑day SMA of $8.71 and comfortably above the 50‑day SMA, indicating a modest short‑term price stability while the 200‑day SMA remains higher, suggesting a longer‑term downtrend. Technical indicators are mixed: RSI sits at 51, implying neutral momentum, but the MACD histogram is negative and the signal line is bearish, hinting at potential downside pressure. The stock currently respects a support level near $8.09 and faces resistance around $9.35, with a calculated upside of roughly 14% based on a DCF fair value of $16.06. Volatility is elevated at 32% over the past 30 days, yet beta is sub‑1 (0.94), indicating the share moves slightly less than the broader market. Fundamentally, the company posted 13% revenue growth, a strong gross margin of 80%, and a free cash flow generation of $9.3 M, supporting its cash‑rich balance sheet (cash $20.7 M vs debt $2.0 M). However, the trailing P/E of 97 dwarfs the industry average of 27, making the valuation appear stretched on a pure earnings basis, while the forward P/E of 20 aligns more closely with growth expectations. Recent material news highlights a 34% rise in net income, a 22% jump in adjusted EBITDA, a $1.1 M share repurchase, and insider buying by a ten‑percent owner, all of which reinforce confidence in the company's operational momentum. Overall, the blend of solid cash flow, improving profitability, and upside potential from valuation models suggests a cautiously optimistic outlook, but the high current P/E and elevated volatility warrant careful monitoring.
Investors should weigh the near‑term technical resistance and bearish MACD against the fundamental upside and recent earnings beat. The stock’s low dividend yield (zero) and modest market cap (~$124 M) also limit income‑focused strategies, positioning JYNT more as a growth‑oriented play with a potential price correction risk if earnings fail to sustain momentum.
Investors should weigh the near‑term technical resistance and bearish MACD against the fundamental upside and recent earnings beat. The stock’s low dividend yield (zero) and modest market cap (~$124 M) also limit income‑focused strategies, positioning JYNT more as a growth‑oriented play with a potential price correction risk if earnings fail to sustain momentum.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 7/10
Key Factors
- Price near technical support with modest upside
- Recent earnings beat and share repurchase
- Insider buying indicating confidence
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- 13% revenue growth and expanding margins
- Forward P/E of ~20 suggesting reasonable valuation
- Strong free cash flow and low leverage
Long Term
> 3 yearsPositive
Model confidence: 7/10
Key Factors
- DCF fair value indicates ~14% upside
- Sustainable cash‑rich balance sheet
- Growth trajectory in a cash‑based healthcare niche
Key Metrics & Analysis
Financial Health
Revenue Growth13.30%
Profit Margin5.72%
P/E Ratio97.0
ROE7.00%
ROA0.61%
Debt/Equity13.18
P/B Ratio8.2
Op. Cash Flow$4.1M
Free Cash Flow$9.3M
Industry P/E26.9
Technical Analysis
TrendNeutral
RSI51.2
Support$8.09
Resistance$9.35
MA 20$8.71
MA 50$8.66
MA 200$9.14
MACDBearish
VolumeIncreasing
Fear & Greed Index89.61
Valuation
Fair Value$16.06
Target Price$10.00
Upside/Downside14.55%
GradeUndervalued
TypeGrowth
Risk Assessment
Beta0.94
Volatility32.33%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.